Trial results show that patients with hemophilia A with or without factor VIII inhibitors treated with emicizumab-kxwh every 4 weeks can have clinically meaningful control of bleeding.
Drug maker Genentech has announced the full results from the phase 3 HAVEN 3 and HAVEN 4 trials of emicizumab-kxwh (Hemlibra) in patients with hemophilia A at the World Federation of Hemophilia (WFH), held in Glasgow, Scotland from May 20-24, 2018. The results show that patients with hemophilia A with or without factor VIII inhibitors treated with emicizumab-kxwh every 4 weeks can have clinically meaningful control of bleeding.
In November 2017, the FDA first approved the drug for the treatment of hemophilia A for routine prophylaxis in adult and pediatric patients with factor VIII inhibitors based on the results from the HAVEN 1 and HAVEN 2 trials.
“Hemlibra is the first medicine to show superior efficacy to prior factor VIII prophylaxis, the current standard of care therapy, as demonstrate by a statistically significant reduction in treated bleeds in the HAVEN 3 study intra-patient comparison,” said Johnny Mahlangu, MB BCh, FCPath, MMed, faculty of health sciences, University of the Witwatersrand and NHLS, in a statement.
The HAVEN 3 trial is a randomized, multicenter, open-label, phase 3 study to evaluate the efficacy, safety, and pharmacokinetics of emicizumab-kxwh prophylaxis versus no prophylaxis (episodic versus on demand factor VIII treatment, respectively) in patients with hemophilia A without factor VIII inhibitors, and included 152 patients with hemophilia A who were aged 12 or older and were previously treated with factor VIII therapy either as needed or for prophylaxis. Patients who had been previously treated with on demand factor VIII were randomized 2:2:1 to receive:
Patients who were previously treated with factor VIII prophylaxis received subcutaneous emicizumab-kxwh prophylaxis at 3 mg per week for 4 weeks, followed by 1.5 mg per week until the end of the study (Arm D).
Per protocol, any episodic treatment of breakthrough bleeds with factor VIII therapy was permitted. Researchers found that patients that received emicizumab-kxwh prophylaxis every week or every 2 weeks showed a 96% (P <.0001) and 97% (P <.0001) reduction in treated bleeds, respectively, compared to those who received no prophylaxis.
Notably, in an intra-patient comparison, patients that had previously participated in a prospective non-interventional study, once-weekly emicizumab-kxwh prophylaxis showed superior efficacy compared to prior factor VIII prophylaxis, which is the standard of care for people with hemophilia A without factor VIII inhibitors, demonstrated by a 68% reduction (P <.0001) in treated bleeds.
HAVEN 4 is a single-arm, multicenter, open-label phase 3 study of subcutaneous emicizumab-kxwh dosed every 4 weeks. The study included 48 patients aged 12 or older with hemophilia A with or without factor VIII inhibitors who had previously been treated with either factor VIII or bypassing agents.
The trial was separated into a pharmacokinetic run-in and an expansion cohort. All patients in the pharmacokinetic run-in (n = 7) had received previous on-demand treatment. This cohort received subcutaneous emicizumab-kxwh at 6 mg in order to fully characterize the profile after a single dose in 4 weeks. This period was followed with 6 mg every 4 weeks for at least 24 weeks.
Conversely, patients in the expansion arm (n = 41) received subcutaneous emicizumab-kxwh prophylaxis at 3 mg per week for 4 weeks, followed with 6 mg every 4 weeks for at least 24 weeks. In addition, episodic treatment of breakthrough bleeds with factor VIII therapy or bypassing agents (depending on the patients factor VIII inhibitor status) was permitted per study protocol.
Researchers found that patients with or without factor VIII inhibitors who received emicizumab-kxwh every 4 weeks had a median annualized bleeding rate for treated bleeds of 0.0 (interquartile range, 0.0-2.1) with 56.1% (95% CI: 39.7%-71.5%) of people experiencing 0 treated bleeds and 90.2% (95% CI: 76.9%-97.3%) experiencing 3 or fewer treated bleeds.
Data from both the HAVEN 3 and HAVEN 4 trials are being submitted to regulatory agencies around the globe to support product approval.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More